[General principles of antihypertensive treatment].
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D003000:Clonidine / Q000627:therapeutic use; D005500:Follow-Up Studies; D005730:Ganglionic Blockers / Q000627:therapeutic use; D006145:Guanethidine / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D007024:Hypotension, Orthostatic / Q000209:etiology; D008750:Methyldopa / Q000627:therapeutic use; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use; D012964:Sodium / Q000378:metabolism; D013610:Tachycardia / Q000209:etiology; D014655:Vascular Resistance / Q000187:drug effects; D014666:Vasomotor System / Q000187:drug effects; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000959:Antihypertensive Agents; D005730:Ganglionic Blockers; D046948:Secologanin Tryptamine Alkaloids; D006830:Hydralazine; D008750:Methyldopa; D012964:Sodium; D003000:Clonidine; D006145:Guanethidine
Principes généraux du traitement anti-hypertenseur